JoVE Logo
Faculty Resource Center

Sign In

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

DOI :

10.3791/59629-v

July 22nd, 2019

July 22nd, 2019

10,679 Views

1Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, 2Department of Immunology, Mayo Clinic, 3Division of Hematology, Mayo Clinic

Here, we present a protocol to genetically edit CAR-T cells via a CRISPR/Cas9 system.

Tags

CRISPR Cas9

-- Views

Related Videos

article

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

article

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

article

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

article

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

article

A Spheroid Killing Assay by CAR T Cells

article

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

article

In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells

article

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

article

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence

article

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved